Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016860 · ClinicalTrials.gov registry record · Phase 1
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01016860 is a Phase 1 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 16 participants.
The verdict
NCT01016860, a Phase 1 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has been given to over 185 people with cancer.
Interventions
- DRUG irinotecan
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016860
The ClinicalTrials.gov registry entry for NCT01016860 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan is the first listed.
NCT01016860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01016860 about?
NCT01016860 is a clinical study titled "OSI-906 and Irinotecan in Patients With Advanced Cancer". This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has be...
What is the current status of trial NCT01016860?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01016860?
The interventions under investigation include: irinotecan (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01016860?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.